Article
Engineered antibodies targeted to bacterial surface integrate effector functions with toxin neutralization to provide superior efficacy against bacterial infections
2024-09-25
Abstract excerpt
Anti-bacterial monoclonal antibody (mAb) therapies either rely on toxin neutralization or opsonophagocytic killing (OPK). Toxin neutralization protects the host from toxin-induced damage, while leaving the organism intact. OPK inducing antibodies clear the bacteria but leave the released toxins unencountered. Infection site targeted anti-toxin antibodies (ISTAbs) that we report here addresses this binary paradigm...
Topics
Open a Topic to create a Post that cites this publication.
- Antimicrobial Resistance in Staphylococcus
- Bacillus and Francisella bacterial research
- Bacterial Genetics and Biotechnology
- Bacteriophages and microbial interactions
- Clostridium difficile and Clostridium perfringens research
- Escherichia coli research studies
- Streptococcal Infections and Treatments
- Viral gastroenteritis research and epidemiology
Identifiers and source
- Literature Corpus work
- e2969902-1647-5972-888b-66f4db8b0ecb
- DOI
- 10.1101/2024.09.23.24313920
